KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares RepurchasedShort-Term Debt repayments
Ratios

Emergent BioSolutions (EBS) Short-Term Debt repayments (2019 - 2024)

Emergent BioSolutions (EBS) has 4 years of Short-Term Debt repayments data on record, last reported at $222.7 million in Q3 2024.

  • For Q3 2024, Short-Term Debt repayments rose 471.03% year-over-year to $222.7 million; the TTM value through Jun 2025 reached $222.7 million, up 97.96%, while the annual FY2024 figure was $284.2 million, 28.74% down from the prior year.
  • Short-Term Debt repayments reached $222.7 million in Q3 2024 per EBS's latest filing, up from $56.5 million in the prior quarter.
  • Across five years, Short-Term Debt repayments topped out at $353.0 million in Q3 2020 and bottomed at $5.0 million in Q1 2024.
  • Average Short-Term Debt repayments over 3 years is $132.0 million, with a median of $47.8 million recorded in 2023.
  • Peak YoY movement for Short-Term Debt repayments: skyrocketed 2253.33% in 2020, then tumbled 83.76% in 2024.
  • A 3-year view of Short-Term Debt repayments shows it stood at $353.0 million in 2020, then crashed by 96.6% to $12.0 million in 2023, then surged by 1755.83% to $222.7 million in 2024.
  • Per Business Quant database, its latest 3 readings for Short-Term Debt repayments were $222.7 million in Q3 2024, $56.5 million in Q2 2024, and $5.0 million in Q1 2024.